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LA INGENIERÍA DE FRAGMENTOS DE ANTICUERPOS: IMITANDO Y EXPANDIENDO EL SISTEMA INMUNE
Abstract—Since genetic engineering of humanized murine monoclonal antibodies was fi rst demonstrated over two decades 
ago, antibody engineering technologies have evolved based upon an increasing understanding of the mechanisms involved in 
antibody generation in vivo, and a constant search for alternative routes to evolve and exploit the characteristics of antibodies. 
As a result, antibody engineers have devised innovative strategies for the rapid evolution and selection of antibodies and novel 
antibody designs (i.e., antibody fragments). Phage display, cell display and ribosome display technologies, which comprise the 
core of the currently available technologies for the discovery and preparation of such antibodies, are reviewed herein. This article 
intends to communicate the state-of-the-art technology available for the engineering of antibodies to a general readership interested 
in this important fi eld. Therefore, important immunology concepts are introduced before detailed descriptions of the three 
antibody engineering technologies are presented in later sections. A comparison of these methodologies suggests that despite the 
predominance of phage display for the engineering of antibody fragments in the past 20 years, cell display and ribosome display 
will likely gain importance in the selection and discovery of the antibody fragments in the future. Finally, these technologies are 
likely to play an important role in the production of the next generation of antibody-based therapeutics.
Keywords— Antibody engineering, Phase display, Cell display, Ribosome display, Antibody humanization.
Resumen—Las tecnologías para la ingeniería de anticuerpos han evolucionado durante las últimas dos décadas, desde la 
demostración de la posibilidad de humanizar anticuerpos monoclonales de ratón mediante ingeniería genética, apoyadas en el 
creciente entendimiento de los mecanismos involucrados en la generación de anticuerpos in vivo, y en una búsqueda constante 
de rutas alternativas para evolucionar y explotar sus características. Es así como los ingenieros de anticuerpos han desarrollado 
estrategias innovadoras para la evolución y selección de anticuerpos y de novedosos diseños de anticuerpos conocidos como 
fragmentos de anticuerpos. Esta revisión se enfoca en tres tecnologías que comprenden el núcleo de las tecnologías actualmente 
disponibles para el descubrimiento y preparación de tales anticuerpos: la presentación en fagos, la presentación en células, y la 
presentación en ribosomas. Este artículo busca presentar el estado del arte de estas tecnologías a un grupo general de lectores 
interesados en este campo, por lo que inicialmente se introducen importantes conceptos de inmunología requeridos para 
comprender en detalle las tecnologías discutidas. Una comparación de estas metodologías para la ingeniería de anticuerpos sugiere 
que a pesar del dominio de las tecnologías basadas en la presentación en fagos durante los últimos 20 años, en los próximos años 
la presentación en células y la presentación en ribosomas probablemente ganarán importancia para la selección y descubrimiento 
de fragmentos de anticuerpos. Finalmente, es probable que estas tecnologías jueguen un papel importante en la producción de la 
siguiente generación de terapéuticos basados en anticuerpos.
Palabras clave— Ingeniería de anticuerpos, Presentación en fagos, Presentación en células, Presentación en ribosomas, 
humanización de anticuerpos.
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I. INTRODUCTION
Most recent reviews in the fi eld of antibody engineering have examined in great detail 
the dynamics of the clinical transfer of antibody 
engineering technology developed for therapeutic 
purposes. Substantial emphasis has been placed on the 
characteristics of the antibodies being used, their targets 
and mechanisms, and the opportunities and challenges 
for the continuous progress of the fi eld, particularly the 
remaining limitations of the state-of-the-art technology 
for antibody production [1-4]. Because of this emphasis, 
previous reviews have been directed toward a relatively 
specialized audience of antibody engineers in need of 
constant feedback on the increasing number of antibody-
based therapeutic strategies under clinical trials, since the 
outcome of these trials signifi cantly affects new research 
initiatives and thus the evolution of the fi eld. However, the 
possibility to engineer human antibodies and novel related 
proteins against virtually any target has broad biomedical 
impact, providing for a means to neutralize (i.e., render 
inactive through antibody binding) key soluble proteins or 
receptors involved in the onset or progression of disease 
(e.g., chronic infl ammation, cancer), or develop a means 
to target and release additional therapeutic cargos to 
specifi c cell populations (e.g., cancer cells) in the body. 
Hence, this short review article is aimed at a more general 
readership, who may have an interest in this technology 
but may not be acquainted with the immunology concepts 
required for understanding the relevant literature in this 
fi eld. This review surveys the current technologies for 
engineering antibodies with a focus on the methodologies 
for developing antibody fragments and novel engineered 
proteins inspired by the structural components of 
complete antibodies. These novel technologies provide 
an important alternative to traditional antibody-based 
technologies and are often better suited for certain 
biomedical applications than conventional monoclonal 
antibodies. 
II. KEY IMMUNOLOGY CONCEPTS
This section introduces important immunology 
concepts essential to understanding antibody engineering 
strategies, their rationale, relevance, challenges and 
limitations. In some cases, the in vivo processes are 
contrasted with their engineered counterparts, although 
additional analogies will become evident throughout later 
sections of the article. These concepts may lie in any of 
three categories: (i) antibody structure and (ii) function, 
and (iii) diversity of the immune repertoires. Figure 1 
summarizes basic information regarding antibody structure 
and function, and Fig. 2 and Table 1 detail the concepts 
related to antibody diversity.
Fig. 1. Structure and folding of immunoglobulins. (A) Schematic of the general structure of the four immunoglobulin G (IgG) isotypes, the 
predominant immunoglobulin class used in antibody engineering, which differ in the number and arrangement of disulfi de bonds and the heavy-
chain component (γ1, γ2, γ3 and γ4, respectively; not shown in fi gure). The effector functions of each subisotype are indicated, since the ability to 
activate different receptors present in immune cells (i.e., effector functions mediated by Fc gamma receptors) plays a critical role in isotype selection 
for antibody engineering, and removal of constant domains can also prevent complement activation (e.g., C1) and other immune responses [5]. (B) 
Folding of an immunoglobulin light chain depicting the β-pleated sheet structure in each domain, the conserved disulfi de bond and the localization of 
the hypervariable regions (CDRs) in three loops joining β-strands of the variable domain. Images modifi ed from Goldsby et al. 2003 [6].
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Antibodies, or immunoglobulins, are heterodimers 
composed of two identical light (L) chains and two 
identical heavy (H) chains. One light chain is covalently 
linked to one heavy chain by a disulfi de bond, and the 





) by additional disulfi de bonds between 
heavy chains (Fig. 1A). The heterodimeric structure is 
further stabilized by non-covalent interactions, such 
as hydrophobic interactions, hydrogen bonds, and 
salt-linkages. Early investigations into the structure of 
antibodies using enzymatic digestion helped to elucidate 
the Y-shaped structure of antibodies. Digestion with 
papain resulted into two antigen-binding fragments (Fab) 
and one crystallizable fragment (Fc), while digestion 
with pepsin resulted in a single antigen binding fragment 
comprised of two antigen-binding domains (F(ab’)
2
) [6]. 
Genetic analysis of antibodies isolated from 
human subjects provided further understanding of the 
immunoglobulin structure and variability. The fi rst 
110 amino acids of the N-terminal segments of H and L 





 domains, which account for most of the differences 
in specifi city displayed by native antibodies [6]. The 




 for a given antibody 
determine its idiotype (i.e., antigenic determinants). The 




 chain is the antigen binding 
pocket, and the specifi city of antibody-antigen binding is 
predominantly controlled by 6 segmented, hypervariable 
loops called the complementarity-determining regions 
(CDRs) that extend from a highly ordered β-pleated 
structure characteristic of the immunoglobulin folding 
(Fig. 1B). While the CDRs are primarily responsible for 
antigen specifi city, the whole variable domain serves as 
a scaffold for the correct presentation of the binding site, 
and mutations along its sequence also infl uence, to a minor 
extent, antibody affi nity [4,6].
The remaining amino acids of the H and L chains are 





). Heavy chains have 3 to 4 C
H
 domains, whereas 
L chains have a single C
L
 domain (Fig. 1) encoded by one 
of two light-chain genes, kappa (κ) or lambda (λ). The 
class of an antibody is determined by its heavy chain, of 
which there are fi ve different chains or isotypes: α, δ, ε, 
γ and μ.  Immunoglobulin G (IgG) is made up of two γ 
heavy chains and is the most abundant (~80% of total 
serum immunoglobulin) and most studied immunoglobulin 
class for antibody engineering (Fig. 1A). The structure and 
functions of the other immunoglobulin classes (i.e., IgA, 
IgD, IgE and IgM), which play important roles in adaptive 
immunity, will not be discussed due to their minor role in 
current antibody engineering applications. Subtle amino 
acid differences encoded in the C
H
 germ-line genes lead to 
a further division of isotypes into subisotypes or subclasses. 
In humans, for instance, there are four subisotypes of γ 
heavy chains (γ1, γ2, γ3, and γ4) with 90-95% homology 
between their genes. Additionally, different members of the 
same species may have multiple alleles for the same isotype 
genes, which determine the antibody allotype. 
The isotype and subisotype of an antibody strongly 
impact the structure and effector functions of the Fc region. 
Because of this, the selection of the isotype is relevant for 
engineering antibodies, since different applications may 
require the mediation of different effector functions or, 
even more, their absence [4,5]. The existence of different 
Fc regions modulates the binding to specifi c Fc receptors 
found in immune effector cells ―Fc gamma receptors 
(FcγR) in the case of IgG―, which trigger different effector 
functions upon binding of the antibody-antigen complexes, 
such as complement activation (component C1), antibody-
dependent cell-mediated cytotoxicity (ADCC), opsonization 
(phagocytosis by macrophages and neutrophils) and 
transcytosis (crossing of epithelial layers). In the case of 
IgG, the Fc region also has the ability to bind to the neonatal 
Fc receptor (FcR
N
), which plays a critical role in the 
regulation of IgG pharmacokinetics, since the binding to the 
FcR
N
 constitutes a salvage mechanism that recycles IgG and 
therefore allows for prolonged serum half-lives. Despite the 
importance of the Fc fragment in the modulation of effector 
functions, and although it is amenable to tailoring antibody 
pharmacokinetics (i.e., select antibodies with increased 
affi nity to FcR
N
) and has the ability to trigger specifi c 
effector functions (i.e., ADCC to tumor cells expressing 
the target antigen), the antibody engineering technologies 
discussed in this article focus on the antibody-antigen 
interaction, and are optimized and selected in formats 
devoid of Fc regions [2,7]. However, it should be noted that 
the modularity of the antibody structures also allows for the 
grafting of Fc regions into optimized antibody fragments 
(e.g., variable regions), although this usually requires 
the expression of the antibody fragment in eukaryotic 
expression systems [8]. 
The ability of the immune system to generate antibodies 
against virtually any antigen depends on its ability to 
generate a suffi cient number of antibodies that can be 
selected based on their affi nity for binding the antigen. The 
mechanisms involved in the generation of such diversity 
span different levels of cell physiology and are tightly 
associated with the maturation and differentiation of B cells, 
which are responsible for their production and secretion in 
vivo [6]. The main mechanisms involved in the generation 
of antibody diversity, as depicted in Fig. 2, are further 
explained in Table 1, which account for the tremendous 
diversity (>1010) of the immune repertoire. In addition, the 
role of these mechanisms or their analogues in generating 
antibody diversity in existing antibody engineering 
technologies is indicated.
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Fig. 2. Rearrangement of immunoglobulin genes responsible for generating antibody diversity. The cartoon depicts the three main sources 
of variation resulting in the antibody repertoire diversity: combinatorial joining of the germ line V, D, J (H chain) or V and J (L chain) segments; 
imprecise joining of the coding sequences (junctional fl exibility) and random addition and deletion of nucleotides at the joint between segments; 
and fi nally somatic hypermutation along the VJ and VDJ regions for affi nity maturation during a T-cell-dependent secondary immune response [9]. 
Dotted (vertical) lines indicate non germ line encoded residues.
Table 1. Principal sources of antibody diversity in humans. The overall diversity is believed to exceed 1010. Analogue mechanisms, such as error 
prone amplifi cation of the variable regions are harnessed for the generation of diversity in synthetic and semisynthetic antibody libraries. Similarly, 
all the mechanisms below account for the diversity available in in vivo models for antibody generation, such as transgenic mice expressing 
repertoires of human antibody genes [6,9-11].
Source of variation Mechanism Calculated diversity Role in antibody engineering
Combinatorial V-J 
and V-D-J joining





 and 6 J
H
 segments.
Light chain: combinations of 40 V
L
 and 5 J
L
 
kappa chains; and of 30 V
L




8262 for Heavy chain 
and 320 for Light 
chain.
In vitro combinatorial assembly of the 
naïve immune repertoire (V-J and 
V-D-J segments).
Construction of synthetic libraries with 







Imprecise joining of the coding sequences 




Variation in the sequence of the coding joint 
due to imprecise cutting of the hairpin struc-
ture formed during the initial recombination 
process, leaving a single strand at the end of 
the coding sequence. A repair enzyme adds 
complementary nucleotides to this strand 















 joining process by a terminal 
deoxynucleotidyl transferase (i.e., addition of 




Mutations along the whole VJ and VDJ 
segments, although the mutations are usually 
concentrated in the CDR regions probably due 
to their major contribution to the affi nity matu-
ration of the antibodies. The process occurs at 
a frequency ~ 103 per base pair per generation.
Undetermined Error prone amplifi cation of the varia-
ble regions.
Site-directed mutagenesis at the CDRs. 
Combinatorial ligation of CDR-enco-
ding regions. 
[Important for affi nity maturation].
Possible combina-
torial association 
of heavy and light 
chains
Combinatorial association of 8262 heavy 
chains and 320 light chains.
2.64x106 Direct amplifi cation of the antibody 
repertoire (assembled genes) from 
immunized animals by RT-PCR.
Ligation of synthetic variable light 
and heavy genes.
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III. ENGINEERING ANTIBODY FRAGMENTS
The modular structure of antibodies has enabled the 
customization and engineering of high affi nity binders 
in a variety of ways. Before discussing the technologies 
developed for the design and discovery of antibody 
fragments, the available antibody fragment formats are 
presented, since those technologies, as will be noted in 
section IV, are only suited for particular antibody formats. 
Figure 3 depicts the available battery of antibody 
fragments derived from the parental IgG structure. 
The seminal work on the engineering of these new sets 
of antibody formats was conducted on Fab fragments 









)―, and on single-chain variable fragments 
(scFv), a further simplifi cation of the Fab structure 





 fragments with a peptide linker [1]. The 
scFv format rapidly popularized, and is probably the most 
widely used antibody fragment today, mainly due to the 
advantages of directly linking the heavy and light domain 
genes. Linking these domains at the genetic level not only 
simplifi ed the recombinant DNA methods involved in their 
processing, but signifi cantly increased the stability of the 
structure and eliminated the folding problems encountered 
with prokaryotic expression systems (e.g., E. coli) during 
selection and production of antibodies with disulfi de bonds 
[2,8]. Interestingly, the incorporation of the peptide linker 
and the variation of its length has been found to control 
the dimerization properties of the scFv fragments, with 
shorter sequences resulting in increasing valency (diabody, 
triabody and tetrabody formats have been produced). The 





 domains of one scFv promotes the formation 
of bispecifi c scFv by noncovalent interactions between the 
variable domains of a second scFv [3]. 
The maximum simplifi cation of the antibody 





 domain (i.e., only 3 CDRs). The initial 
attempts to derive high affi nity binders using dAb were 
not encouraging, resulting in the selection of fragments 
displaying signifi cant decreases in binding affi nity, 
but most importantly, poor stability and a tendency to 
aggregate [1]. Nevertheless, the fi nding of dAb naturally 
occurring in camels, which displayed high affi nity and 
stability, inspired the design of new dAb circumventing 
these problems, in a process termed “camelization” 
[12]. Despite the success of the camelization approach, 
the therapeutic applications of such antibodies were 
limited due to the potential immunogenicity associated 
with using non-human scaffolds in the variable region 
design [2]. Only recently, Winter and coworkers, in their 
efforts to characterize a set of dAbs produced against hen 
egg lysozyme (HEL), discovered an antibody domain 
displaying similar properties to those found in camel and 
llama V
H
H Abs but without recurring to camel-based 
scaffolds (i.e., camelising mutations). The same group 
also devised a methodology for the generation of equally 
stable and aggregation-resistant domain antibodies [13]. 
One important realization of this work was the increased 
understanding of the role of the CDRs in determining 
the thermodynamic stability, as well as expression and 
purifi cation yields, of antibodies [11,12]. 
Fig. 3. Schematic of the most common engineered antibody fragments. The molecular weight (MW) of the fragments varies from 15 KDa for the 




 respectively, with serum half-lives (t) of 0.05 h, through 100 KDa in single-chain variable fragments 
(scFv) with a crystallizable fragment (Fc), scFv-Fc, and a half-life of 12 h, to 165 KDa in the trispecifi c Fab (antigen binding fragment), F(ab’)
3
. dsFv: 
disulphide-stabilized scFv. Image modifi ed from Carter, 2006 [3]; pharmacokinetics and MW data was taken from Holliger and Hudson, 2005 [2].
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IV. ANTIBODY ENGINEERING TECHNOLOGIES
The discovery of the hybridoma technology in 
1975 enabled the production of monoclonal antibodies 
(mAbs) and paved the way for the evolution of the 
Antibody Engineering fi eld [14]. The therapeutic 
potential of such technology became evident in 1984, 
when Winter and collaborators demonstrated an ability 
to form chimeric antibodies with murine antigen-binding 
domains and complete human effector functions (i.e., 
Fc region). In 1986, the same group developed the 
groundbreaking antibody humanization technology, 
which involves transferring the CDR regions of a murine 
monoclonal antibody into a human immunoglobulin 
scaffold, signifi cantly reducing the immunogenicity 
issues associated with murine antibodies [15]. Current 
antibody engineering technologies have surpassed many 
of the challenges imposed by the selection of antibodies 
using murine cell lines (i.e., hybridoma technology), 
eliminating the need for humanization by enabling the 
production of fully human antibodies in vitro or in other 
engineered animal models. Hence, the technologies 
presented in this section will focus on these alternative 
methods for the selection and production of human 
antibody fragments. 
4.1 Antibody libraries
As explained in section II, the diversity of the 
immune repertoire is critical for the successful isolation 
and production of high affi nity antibodies [16]. Indeed, 
library characteristics, such as size (overall diversity) and 
quality (i.e., number of functional combinations), dictate 
the ability to express relevant antibody fragments against 
a particular antigen [1,17,18]. Therefore, the screening 
technologies presented in the next section are strongly 
dependent on the characteristics of the antibody library 
being used.
Due to the complexity of the immune repertoire, the 
initial approaches for the construction of antibody libraries 
followed a simple strategy: the amplifi cation of assembled 
antibody genes after mice immunization by means of RT-
PCR using a set of primers designed for the amplifi cation 
of all antibody genes and based on the variable region 
frameworks (already known by the time and deposited in 
data bases: Kabat and V-base database) [19]. However, 
this approach still used mice for the generation of the 
assembled antibody genes after immunization, therefore 
presenting only partial advantages. An additional level of 
complexity was included by applying a similar strategy 
for the amplifi cation of naïve libraries (i.e., gene segments 
before recombination) from non-immunized animals 
followed by in vitro combinatorial assembly of the 
antibody repertoire [10]. 
Despite these signifi cant advances, the antibody 
fragment screening and production technologies relied on 
non-mammalian systems, which suffer from inadequate 
expression levels and other problems derived from 
differences in codon usage. As a result, the development 
of semisynthetic and later of fully synthetic human 
antibody libraries represented an important achievement 
for the antibody engineering fi eld. These libraries can 
now be optimized for expression according to the 
selection technology and desired expression system, have 
modular designs that allow relatively easy interconversion 
between different antibody formats, and signifi cantly 
simplify laborious DNA manipulation steps. In addition, 
synthetic libraries are not limited by the bias introduced 
in germ-line repertoires throughout evolution, such as the 
tolerance mechanism against selection of self-antigens, 
and therefore enable, at least in theory, the discovery and 
selection of antibodies with no representation in natural 
immune repertoires [4,20].
Figure 4 presents the designs of the most advanced 
human synthetic libraries currently available, which are 
known as Human Combinatorial Antibody Libraries 
(HuCAL) [17,21]. Initially introduced in 2000, this 
synthetic library implemented innovative concepts for 
the generation of diversity, including diversity not only 
in the CDRs but also in the framework regions, which 
are known to play a role in CDR conformation. In 
addition, the diversity introduced in the CDR libraries 
is biased towards sequences predominant in the human 
immune repertoire (by using trinucleotide cassette 
mutagenesis), which facilitates the selection of antibody 
fragments with minimal or no immunogenicity (human 
anti-human antibody, HAHA) [9,16]. It is worth noting 




 gene families, as well 
as the families selected, were carefully analyzed by 
bioinformatics means to achieve suffi cient diversity while 
preventing excessive complexity of the library. Indeed, 
this library only uses 7 master genes for heavy chains 
and 7 genes for light chains corresponding to consensus 
sequences for seven V
H
 and seven V
L
 germ-line families 
which were found to account for more than 95% of the 
human antibody diversity observed in vivo. The library 
was initially developed in scFv format, but is now also 
available for Fab fragments [10]. Some characteristics 
of the newest versions of the HuCAL library (Fig. 4B 
and 4C), HuCAL Fab 1 and HuCAL GOLD, that require 
special attention are: (i) the absence of cysteine residues in 
the constant domains (eliminated to avoid problems during 




) is covalently 
attached to pIII (for phage display, reviewed in next 
section), so that the system depends on the non-covalent 
interactions with the light chain, and (iii) the absence 
of cysteine residues in the CDR regions in the HuCAL 
45Quiroz FG and Sinclair SM. Engineering antibody fragments
GOLD library (to avoid problems with the CysDisplayTM 
technology). Although (ii) may be complicated by light 
chain exchange in a given phage preparation, thereby 
losing the linkage of genotype to phenotype, the authors 
claim that after extensive use of the library this non-
covalent interaction proved very stable [20,21].
Two powerful technologies for screening antibody 
libraries and selecting antibodies of high affi nity for a 
particular antigen involve the display of one (monovalent) 
or several (multivalent) antibody particles on the surface 
of either phage virion, phage display (section 4.2), or 
on the cell surface (i.e., cell wall, cell membrane) of a 
prokaryotic or eukaryotic host, cell display (section 4.3).
4.2 Phage display
Phage display is a powerful biomolecular engineering 
technique for selecting high affi nity binders to biologically 
relevant targets by several rounds of affi nity selection. 
Foreign DNA encoding recombinant peptides or proteins 
is fused to coat protein DNA of bacteriophage such 
that recombinant molecules will be expressed and 
displayed on the outer surface of the phage. This strategy 
effectively links the protein phenotype and genotype (i.e., 
the corresponding DNA carried by the phage) thereby 
enabling the simple identifi cation of the selected proteins 
at the DNA level. In the seminal publication of phage 
display [22], fragment genes of the endonuclease EcoRI 
were fused to the gene III protein (g3p) of fd fi lamentous 
phage to produce “fusion phage” capable of yielding 
peptides with 1000-fold higher affi nity for anti-EcoRI 
antibody. Winter’s group then demonstrated the possibility 
to display functional antigen-binding sites on the surface 
of these phage particles for their evolution [23,24], and 
subsequently contributed to the seminal work on the 
construction of large phage antibody libraries [25]. By 
linking phenotype to genotype, vast libraries of phage 
(109-1012 clones) displaying different fusion proteins can 
be assembled, selected for with simple affi nity techniques 
(Fig. 5A), and quickly identifi ed by conventional DNA 
sequencing [26]. Marks et al. (1991) prepared a library 
of scFv genes from peripheral blood lymphocytes 
isolated from unimmunized human donors by RT-PCR, 
which contained randomly generated heavy and light 
chain variable fragments. After affi nity selection, phage 
displaying scFv demonstrated affi nity for their target 
 
Fig. 4.  Modularity and diversity in synthetic human antibody libraries. (A) General format of the 49 scFv master genes comprising the Human 




 orientation), where the scFv cassette is preceded by a phoA signal sequence (reporter 




 domains are fused by a peptide 
linker; diversity is further incorporated by pre-built CDR3 cassettes libraries yielding a library size of 2x109 (~61% functional sequences). (B) 
HuCAL- Fab 1 library generated from the original HuCAL scFv library, with all master genes in Fab format and library size of 2.1x1010 (~67% 
functional sequences). (C) Most recent version of the HuCAL library, HuCAL GOLD, incorporating diversity in all six CDRs and adapted for 
antibody selection by CysDisplayTM. Images reproduced from (A) Knappik et al. 2000, (B) Rauchenberger et al. 2003 and (C) Rothe et al. 2008 
[10,20,21].
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on par with the affi nity of native antibodies for the same 
target, indicating the utility of phage display for bypassing 
immunization and producing high affi nity binders. Today, 
phage display constitutes the most developed in vitro 
system for the selection of antibody fragments [4,27].
Filamentous phage (Ff), bacteriophage T4, and phage 
λ are the three general types of phage used for phage 
display. Initial bacteriophage studies used fi lamentous 
M13 phage to amplify and isolate single-stranded 
DNA [28], which led to M13-based plasmid constructs 
(M13mp18/19) that have become the basis for most phage 
display systems [29]. While M13-based systems are the 
most developed, bacteriophage T4 and phage λ systems 
have shown equal promise. Bacteriophage T4 are able 
to house signifi cantly larger quantities of DNA [30], and 
phage λ display has shown increased ability to incorporate 
larger proteins and cDNA libraries compared with Ff 
phage display [31].
Phage display has also been used for epitope mapping 
[32] and discovery [33], identifying new receptor-ligand 
pairs [34] and drug discovery [35]. In each case, multiple 
rounds of selection with increasing stringency should yield 
a small set of champion peptides. The hope, and ultimate 
goal, of phage display is that a consensus sequence from 
selected peptides will emerge. Often, the consensus 
sequences are non-obvious amino acid sequences 
that could not have been predicted by rational design 
methods [22]. The success of phage display depends on 
understanding phage biology, methods of display, random 
peptide library limitations, and affi nity selection schemes. 
Phage display methods are named depending upon 
which phage protein has been fused, how many copies of 
the fusion are present in one phage particle, and what type 
of phage vectors are employed, phage and/or phagemid 
vectors [26]. One important characteristic of the phage 
display technology is the control it offers over valency 
of display, since this parameter determines the avidity—
functional affi nity determined by the number of binding 
sites—of the selection strategy and signifi cantly affects the 
affi nity of the selected clones. For instance, high valency 
often results in antibodies with moderate affi nity, since 
the higher, uncontrolled avidity increases the stability 
of the antigen-antibody complex independently of the 
antibody affi nity, whereas monovalent display ensures the 
selection of the antibodies with the highest affi nity for the 
antigen [36]. Type 3 phage display uses phage vectors with 
one copy of recombinant gene III protein (g3p) and will 
generate phage that display 3 to 5 copies of a recombinant 
p3. Type 33 phage display systems contain two copies of 
g3p gene, one recombinant and one wild type and will 
yield multivalent phage particles with recombinant and 
wild-type p3 proteins displayed on the phage surface. 
Type 3+3 phage display systems use two different vectors, 
helper phage vectors and phagemid vectors. Phagemid 
vectors are small plasmids with high transformation 
effi ciency that contain all the necessary components 
for infection, house recombinant DNA encoding the 
antibody-g3p fusion protein, but lack assembly and export 
genes. Phagemid systems, therefore, require helper phage, 
which retain the genes for packaging proteins and wild-
type protein genes. Phagemid vectors are packaged in 
preference to helper phage vectors, but both wild-type and 
recombinant proteins will be displayed. In fact, more than 
90% of the recovered phagemid particles do not display 
antibodies. However, this mechanism ensures that phage 
displaying recombinant g3p generally display a single 
copy on the virion surface [16,36].
Phage and phagemid vectors have been engineered 
extensively and now include antibiotic resistance genes 
for selection, a multiple cloning site (MCS) for easy 
generation of libraries in frame, and optimal promoter 
and packaging signals [22,37]. Phagemid systems are 
generally more stable than phage vectors, which can 
spontaneously delete foreign DNA fragments. Phagemid 
systems are also more tolerant to larger peptide inserts 
and generation of larger libraries is easier [38]. Phagemid 
display, which presents a single copy of a recombinant g3p 
protein, is required for optimal affi nity maturation studies 
like antibody engineering, as display of single proteins 
results in the selection of fewer unique binders without 
interference from the effects of avidity [24]. However, 
phagemid display requires the addition of helper phage at 
specifi c points of the bacterial growth cycle, and therefore 
presents operational diffi culties not characteristic of pure 
phage display.
Recently, a variant of the traditional phage display 
strategy, CysDisplayTM (http://www.morphosys.com/), 
was introduced that facilitates the recovery of antibody 
fragments with ultra-high affi nity [16]. In CysDisplayTM, 
the antibody fragment is linked to the coat protein through 
a disulfi de bond instead of the direct peptide linkage 
when expressed as a fusion protein. Because of this, 
the recovery of the phage particles is easily achieved by 
adding reducing agents and is rendered independent of the 
antibody affi nity to the antigen. 
4.3. Cell display
Cell display, on the other hand, uses an analogous 
system wherein the antibody gene is fused to a protein 
naturally displayed on the outer membrane of a cell, as 
shown in Fig. 5B. Although cell display has been used with 
prokaryotic cells, the most current technology mainly uses 
eukaryotic systems such as yeasts and mammalian cells 
[18,39]. This strategy, in opposition to phage display, only 
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allows for multivalent display, whereby a large number of 
antibody copies are displayed on the outer membrane of the 
cell. While this strategy may be complicated by increased 
avidity compared to monovalent display systems, it benefi ts 
from existing technologies for studying eukaryotic cells, 
such as fl ow-cytometry and fl uorescence activated cell 
sorting (FACS) ,which enable simultaneous selection 
and characterization of antibody fragments kinetics [40]. 
The basic strategy incorporates additional tags in the 
fusion protein in order to quantify the expression levels 
of the antibody fragment (i.e., the valency of the display), 
thus allowing the normalization of the antigen-antibody 
fl uorescence signal to discriminate avidity effects, and also 
for selecting antibody fragments already optimized for high 
expression and the early removal of truncated products 
during the selection process [40].
The implementation of the cell display technology 
in a yeast model may also offer additional advantages 
compared with screening in prokaryotes by phage display. 
For instance, expression biases and growth selection 
introduced by bacteria can skew library diversity. In 
contrast, yeast models have been shown to propagate full 
library diversity along the selection process [18]. Figure 
5B includes additional details about the construction of 
the display system, and compares the design of the fusion 
proteins involved in the two variants of the cell display 
technology herein discussed with the phage display 
method. In addition, a comprehensive comparison of the 
phage display, cell display and ribosome display (reviewed 
in next section) technologies is presented in Table 2.
4.4  Ribosome display
The development of the ribosome display technology 
by Hanes and Plückthun in 1997, based on earlier work 
by Mattheakis et al., 1994, represented a breakthrough in 
the protein engineering fi eld by demonstrating the ability 
to screen libraries of unprecedented size in a cell-free 
system [41-43]. The advantages and disadvantages of this 
novel technology, in contrast with phage and cell display, 
are presented in Table 2; cell-free systems, for instance, 
overcome the basic limitation of library size imposed by 
transformation effi ciency for the previously discussed 
methods [44]. Ribosome display, which has evolved over 
the past 10 years, is now actively used for the development 
of new antibody fragments in various applications 
[17,45,46].
 
Fig. 5.  Schematics depicting the phage and cell display systems. (A) In phage display, clones 
Fig. 5.  Schematics depicting the phage and cell display systems. (A) In phage display, clones carrying antibody fragments with specifi city to the 
desired antigen are bound to the column, whereas the nonspecifi c clones are removed by washing; after elution (e.g., by using protease cleavage) 
the selected clones are amplifi ed by infection, followed by about 2 additional panning rounds. (B) Cell display uses fusion proteins to localize the 
antibody fragments to the cell wall (yeast) or cell membrane (e.g. Aga2 for yeast, PDGFR in mammalian cells), and selection is achieved by FACS 
of a fl uorescently labeled antigen. Images modifi ed from (A) Lee et al. 2007 and (B) Feldhaus and Siegel, 2004, and Ho et al. 2006 [27, 39, 40].
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Although cell-free transcription and translation 
systems were already established, applying cell-free 
systems to screen antibody repertoires was only feasible 
when Hanes and Plückthun (1997) were able to form 
stable mRNA-ribosome-antibody complexes by removing 
the terminal stop codon in the mRNA, which prevented 
the release of the nascent peptide from the ribosome 
during protein synthesis [41]. By including a linker or 
spacer sequence between the peptide and the ribosome, 
they could correctly fold the protein and use stabilized 
mRNA molecules (by modifi cation of the 5’ and 3’ ends 
loops) for a completely in vitro affi nity selection process 
[46]. Figure 6 shows a detailed diagram of the ribosome 
display strategy recently published by Plückthun and 
collaborators, depicting the major steps of the process and 
important methodological aspects [46].
Ribosome display has been developed using either 
prokaryotic gene expression machinery (e.g., bacterial 
extracts) [17] or eukaryotic systems [44,47]. In both cases, 
the technologies are almost indistinguishable, although the 
use of eukaryotic ribosome display allows direct cDNA 
synthesis from the Antibody –Ribosome-mRNA (ARM) 
complexes by in-situ RT-PCR, as demonstrated by He 
and Taussig in 1997, and avoids some technical issues of 
prokaryotic ribosome display related to ARM complex 
disruption during elution of mRNA [44,48]. Hence, 
this approach reduces loss of material during ribosome 
disruption and mRNA recovery, which is critical to 
maximize diversity. 
In 2007, Contreras-Martínez and Delisa proposed a 
variation of the ribosome display technology for the evolution 
of intracellular antibodies [49]. Intracellular ribosome 
display, which makes use of the recently discovered E. coli 
SecM translation arrest mechanism to allow the formation of 
mRNA-ribosome-antibody (fused to SecM signal), enables 
stable stalling of the ribosome (intracellularly) at the SecM 
sequence (serving also as spacer for appropriate folding) 
and subsequent recovery of the complexes by centrifugation. 
Additional selection steps proceed in a similar fashion to 
standard ribosome display [49].
Fig. 6.  Antibody selection by ribosome display. A library comprising the antibody repertoire (in the form of PCR product) is ligated into a 
Ribosome Display Vector (pRDV) to incorporate required 5’ and 3’ sequences (e.g. spacer, promoter, etc.), followed by in vitro translation. Stable 
mRNA-antibody complexes are formed due the absence of a stop codon, which stalls the ribosome at the end of the mRNA molecule, then, selection 
is performed by binding to an immobilized antigen and washing unbound complexes. The eluted mRNA is reverse transcribed and amplifi ed (with 
or without incorporation of headers and tails) and used for a new round of selection or the analysis of single clones by cloning into expression 
vectors and expressing them in a suitable system (i.e., cell-free, yeast, bacteria, etc.). Image modifi ed from Zahnd et al,. 2007 [46].
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4.5 Other aspects of the antibody engineering process
The fl exibility in the design of antibody fragments 
(Fig. 3) and the variety of technologies available for their 
discovery and optimization, as discussed in Table 2, allow 
for myriad possibilities when tailoring the properties of 
these unique proteins according to the design parameters 
dictated by the intended application. The readers are 
strongly encouraged to examine excellent recent review 
articles discussing some important aspects of the 
antibody engineering process that were not the subject 
of this review, including: antibody characterization (i.e., 
quantifi cation of kinetics, stability, immunogenicity, 
etc.) [1,4], pharmacokinetics of monoclonal antibodies 
and antibody fragments (of particular relevance for 
imaging applications and cancer therapy) [50,51], current 
expression systems for the production of antibody 
fragments [8,52], and fi nally, design of antibody-based 
therapeutics, an active area of research that involves 
engineering of the antibody fragments at all levels, 
particularly tailoring the effector functions of the antibody 
fragments which may involve the engineering of the Fc 
region [3,53-55]. 
V. CONCLUSION
The ability to rapidly engineer antibodies against 
virtually any antigenic biomolecule, from mRNA to small 
haptens to big antigenic particles or even molecules with 
cryptic epitopes (as in the case of dAb), with unprecedented 
affi nities, effector functions (i.e., bispecifi c antibodies, 
catalytic antibodies, intrabodies, etc.) and stability, has been 
the result of the powerful antibody discovery technologies 
implemented in the past 20 years. Although phage display 
has governed the production of antibody fragments since 
its introduction, the new advances in ribosome display 
technology and cell display will probably continue to gain 
importance for the selection of the antibody fragments. 
Expected improvements in cell sorting technology might 
signifi cantly increase the throughput of the cell display 
system, its major limitation as of today, although the recent 
demonstration of antibody maturation by mammalian cell 
display may also stimulate the use of this technology in 
combination with phage display in the late stages of the 
antibody maturation process (i.e., stability, expression, etc.). 
Finally, these technologies are likely to play an important 
role in the production of the next generation of antibody-
based therapeutics.
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